Products
Ficerafusp Biosimilar Fusion Protein (EGFR) for Research
Cat No.: GMP-Bios-INN-1203
Anti-EGFR/ERBB1/HER1 therapeutic antibody (Pre-made Ficerafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ficerafusp (development code BCA101) is a chimeric antibody fusion protein targeting EGFR and TGF-beta receptor type 2. It is developed by Bicara Therapeutics for solid tumors. It is in Phase II/III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1203-1mg | 1mg | 3090 |
| GMP-Bios-INN-1203-10mg | 10mg | |
| GMP-Bios-INN-1203-100mg | 100mg | |
| GMP-Bios-INN-1203-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ficerafusp biosimilar, Fusion Protein targeting EGFR/ERBB1/HER1: Recombinant therapeutic protein targeting EGFR/Epidermal growth factor receptor/Proto-oncogene c-ErbB-1/Receptor tyrosine-protein kinase erbB-1 |
| INN Name | Ficerafusp |
| Target | EGFR/ERBB1/HER1 |
| Format | Fusion Protein |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | 6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC |
| 99% SI Structure | 5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC |
| 95-98% SI Structure | 5gz0:BA:DC/6arp:BA:DC/6aru:CB |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Bicara Therapeutics |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | Cetuximab and Ficerafusp have the same Fv sequence. |
